Vaxcyte, Inc. (PCVX)
PCVX Stock Price Chart
Explore Vaxcyte, Inc. interactive price chart. Choose custom timeframes to analyze PCVX price movements and trends.
PCVX Company Profile
Discover essential business fundamentals and corporate details for Vaxcyte, Inc. (PCVX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jun 2020
Employees
414.00
Website
https://vaxcyte.comCEO
Grant E. Pickering
Description
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Financial Timeline
Browse a chronological timeline of Vaxcyte, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$2.06, while revenue estimate is $12.50m.
Earnings released on 6 May 2026
EPS came in at -$2.30 falling short of the estimated -$1.78 by -29.40%.
Earnings released on 24 Feb 2026
EPS came in at -$1.80 falling short of the estimated -$1.53 by -17.67%.
Earnings released on 4 Nov 2025
EPS came in at -$1.56 falling short of the estimated -$1.27 by -22.83%.
Earnings released on 6 Aug 2025
EPS came in at -$1.22 falling short of the estimated -$1.12 by -8.93%.
Earnings released on 7 May 2025
EPS came in at -$1.04 falling short of the estimated -$1.02 by -1.96%.
Earnings released on 25 Feb 2025
EPS came in at -$1.02 surpassing the estimated -$1.16 by +12.07%.
Earnings released on 5 Nov 2024
EPS came in at -$0.83 surpassing the estimated -$1.10 by +24.55%.
Earnings released on 6 Aug 2024
EPS came in at -$1.10 falling short of the estimated -$0.98 by -12.75%.
Earnings released on 8 May 2024
EPS came in at -$0.85 surpassing the estimated -$1.13 by +24.78%.
Earnings released on 27 Feb 2024
EPS came in at -$1.82 falling short of the estimated -$0.90 by -102.22%, while revenue for the quarter reached $14.45m .
Earnings released on 6 Nov 2023
EPS came in at -$0.91 falling short of the estimated -$0.79 by -15.19%.
Earnings released on 8 Aug 2023
EPS came in at -$0.70 falling short of the estimated -$0.67 by -4.48%.
Earnings released on 8 May 2023
EPS came in at -$0.70 surpassing the estimated -$0.80 by +12.50%.
Earnings released on 27 Feb 2023
EPS came in at -$0.73 surpassing the estimated -$0.84 by +13.10%.
Earnings released on 7 Nov 2022
EPS came in at -$0.93 falling short of the estimated -$0.80 by -16.25%.
Earnings released on 8 Aug 2022
EPS came in at -$0.80 falling short of the estimated -$0.69 by -15.94%.
Earnings released on 9 May 2022
EPS came in at -$0.68 falling short of the estimated -$0.56 by -21.43%.
Earnings released on 28 Feb 2022
EPS came in at -$0.54 falling short of the estimated -$0.46 by -17.39%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%.
Earnings released on 11 Aug 2021
EPS came in at -$0.46 matching the estimated -$0.46.
PCVX Stock Performance
Access detailed PCVX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
